Abstracts tagged "Biomarkers"

Abstract Number: 2344 • 2016 ACR/ARHP Annual Meeting
Inflammation and Glucose Homeostasis Are Associated with Specific Structural Features Among Adults without Knee Osteoarthritis
Alina Stout¹, Mary Barbe², Charles B. Eaton³, Mamta Amin⁴, Fatimah Al Eid¹, Lori Lyn Price⁵, Bing Lu⁶, Grace H. Lo⁷, Ming Zhang⁸, Timothy E. McAlindon⁹ and Jeffrey Driban⁸, ¹Rheumatology, Tufts Medical Center, Boston, MA, ²Temple University School of Medicine, Philadelphia, PA, ³Family Medicine and Community Health( Epidemiology), Alpert Medical School of Brown University, Pawtucket, RI, ⁴Department of Anatomy and Cell Biology, Temple University School of Medicine, Philadelphia, PA, ⁵Clinical Care Research, Tufts Medical Center, Boston, MA, ⁶Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁷Immunology, Allergy, Rheumatology, Baylor College of Medicine, Houston, TX, ⁸Tufts Medical Center, Boston, MA, ⁹Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Adults with osteoarthritis (OA) have greater glucose concentrations and inflammation. It remains unclear if inflammation and glucose homeostasis are related to specific features of…
Abstract Number: 2627 • 2016 ACR/ARHP Annual Meeting
The Effect of Fostamatinib with Methotrexate on Circulating Biomarkers of Synovium, Cartilage and Bone Metabolism: Potential Utility for Clinical Development Decision Making in Rheumatoid Arthriti
Adam Platt¹, Anne C. Bay-Jensen², Martin Braddock³, Martin Jenkins⁴, Kishwar Musa⁵, Christian S. Thudium⁶, Cecilie F. Kjelgaard-Petersen⁶, Emma Graham³, Sue Keeler³, Gill Slynn³, Michael Weinblatt⁷ and Morten Asser Karsdal², ¹Diagnostic Development, AstraZeneca, Cheshire, United Kingdom, ²Rheumatology, Nordic Bioscience, Herlev, Denmark, ³AstraZeneca, Macclesfield, United Kingdom, ⁴Research & Development, AstraZeneca, Macclesfield, United Kingdom, ⁵Laboratory, Nordic Bioscience, Herlev, Denmark, ⁶Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Fostamatinib was developed for the treatment of RA and improved signs and symptoms of RA 1, but did not improve modified Total Sharp Score…
Abstract Number: 3097 • 2016 ACR/ARHP Annual Meeting
Osteoclast Precursor Frequency and Imaging Findings Associated with Arthritis Onset in a Psoriasis Longitudinal Cohort
Ralf G. Thiele¹, Yahui Grace Chiu², Francisco Tausk³, Bethany A. Marston⁴, Changyong Feng⁵, Gregory Dieudonne⁶, Vaseem Chengazi⁶, Sharon Moorehead⁷, Debbie Campbell⁷ and Christopher T. Ritchlin⁸, ¹Medicine, University of Rochester Medical Center, Rochester, NY, ²Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Dermatology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Statistics, University of Rochester, Rochester, NY, ⁶Radiology, University of Rochester, Rochester, NY, ⁷Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁸Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Psoriasis (Ps) precedes joint inflammation by an average of 10 years psoriatic arthritis (PsA) patients. Reports have demonstrated abnormal musculoskeletal imaging findings in psoriasis…
Abstract Number: 478 • 2016 ACR/ARHP Annual Meeting
Evaluation of the Relationship Between Methotrexate Polyglutamation and Efficacy in the Collagen-Induced Arthritis Mouse Model
Rakesh Singh¹, Leon van Haandel², Paul Kiptoo³, Mara L Becker⁴, Teruna Siahaan³ and Ryan Funk⁵, ¹Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, KS, ²2401 Gillham Road, Children's Mercy Hospitals and Clinics, Kansas City, MO, ³Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, ⁴Rheumatology, Children's Mercy Kansas City, Kansas City, MO, ⁵University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Polyglutamate metabolites of methotrexate (MTX) are believed to represent the pharmacologically active form of the drug and have been proposed as a biomarker to…
Abstract Number: 1016 • 2016 ACR/ARHP Annual Meeting
Soluble BAT-3: A New Biomarker for Antisynthetase Syndrome
Baptiste Hervier^1,2, Samra Ouaras², Laurent Gilardin³, Hanane Ouakrim⁴, Damien Amelin⁵, Fleur Cohen⁶, Yurdagul Uzunhan⁷, Yves Allenbach¹, Anne Bourgarit-Durand⁸, Olivier Benveniste⁹ and Vincent Vieillard¹⁰, ¹Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ²CIMI Paris, UMR-S 1135, INSERM & UPMC, Paris, France, ³Internal Medicine, APHP, Hôpital Pitié Salpêtrière, Paris, France, ⁴INSERM UMR-S 1138, Centre des cordeliers & APHP, Cochin Hospital, Laboratory of Pathology, Paris, France, ⁵Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, ⁶Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁷Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ⁸CHU Bondy, Bondy, France, ⁹Pitié-Salpêtrière University Hospital, Paris, France, ¹⁰P&M Curie university, INSERM 543, Paris, France
Background/Purpose: Antisynthetase syndrome (ARS) is an inflammatory myopathy (IM) commonly associated to interstitial lung disease (ILD) and different anti-tRNA-synthetase autoantibodies. The immune mechanisms leading to…
Abstract Number: 1665 • 2016 ACR/ARHP Annual Meeting
Validation of Germ Line Epigenetic Variants Associated with Psoriatic Disease
Remy Pollock¹, Laila Zaman¹, Vinod Chandran² and Dafna D Gladman³, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Heritable epigenetic phenomena may play a role in the parent-of-origin effect observed in psoriasis and psoriatic arthritis (PsA). A previous epigenome-wide association study (EWAS)…
Abstract Number: 2371 • 2016 ACR/ARHP Annual Meeting
Effect of Etanercept on Several Soluble Biomarkers in a Randomized Controlled Trial of Patients with Erosive Hand Osteoarthritis
Féline Kroon¹, Ruth Wittoek², Wing-Yee Kwok¹, Klaus Bobacz³, Dirk Elewaut², Marta Favero⁴, Tom Huizinga⁵, Josef Smolen³, Bert Vander Cruyssen², Ron Wolterbeek⁶, Leonardo Punzi⁷, Gust Verbruggen², Margreet Kloppenburg⁸ and Roberta Ramonda⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Internal Medicine III, Div. of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Rheumatology Unit,Department of Medicine–DIMED, University of Padova, Rheumatology Unit,University of Padova, Padova, Italy, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy, ⁸Rheumatology and Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Erosive hand osteoarthritis (OA) is a hand OA subset with high disease burden, although effective therapies are still lacking and clinical trials are scarce.…
Abstract Number: 2636 • 2016 ACR/ARHP Annual Meeting
No Strong Evidence Supporting Predictors for Successful Dose Reduction or Discontinuation of a Biologic in Rheumatoid Arthritis: A Systematic Review
L. Tweehuysen¹, C.H. van den Ende², F.M.M. Beeren², E.M.J. Been², F.H.J. van den Hoogen^3,4 and A.A. den Broeder³, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ³Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Rheumatology, Radboudumc, Nijmegen, Netherlands
Background/Purpose: Tapering of biologics in rheumatoid arthritis (RA) is based on a trial-and-error disease activity guided strategy, because it is not known in advance which…
Abstract Number: 3151 • 2016 ACR/ARHP Annual Meeting
The Diagnostic and Predictive Value of Anti-Acetylated Peptide Antibodies in RA Patients Starting Methotrexate Treatment
Paul Studenic¹, Stephan Blüml², Holger Bang³, Manuel Unger⁴, Karim Raza⁵, Daniel Aletaha⁶, Josef S. Smolen^7,8 and Günter Steiner⁹, ¹Department of Internal Medicine 3, Division of Rheumatology and Geriatric Medicine, Medical University Vienna, Vienna, Austria, ²Internal Medicine 3; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Rsearch & Development, Orgentec Diagnostika GmbH, Mainz, Germany, ⁴Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁵University of Birmingham, Rheumatology Research Group, Institute of Inflammation and Ageing, United Kingdom, Birmingham, United Kingdom, ⁶Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁷2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ⁸Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁹Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have recently been described in rheumatoid arthritis (RA) patients and may be used as a further diagnostic marker in patients with…
Abstract Number: 482 • 2016 ACR/ARHP Annual Meeting
Comparison of Nonclinical Pharmacology, Pharmacodynamics and Efficacy Response of the Proposed Adalimumab Biosimilar GP2017 to Originator Adalimumab
Antonio Dasilva¹, Ulrich Kronthaler¹, Hans-Peter Hofmann², Vera Koppenburg¹, Melanie Baron³, Cornelius Fritsch⁴, Otmar Hainzl¹ and Andreas Seidl¹, ¹Sandoz Biopharmaceuticals, Holzkirchen, Germany, ²Pre-clinical, Sandoz Biopharmaceuticals, Holzkirchen, Germany, ³Clinical Development, Sandoz Biopharmaceuticals, Holzkirchen, Germany, ⁴Bioassay Support Global Development, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Biosimilars are created to be essentially the same as their reference marketed biopharmaceuticals which have lost exclusivity, and they aim to offer more affordable…
Abstract Number: 1037 • 2016 ACR/ARHP Annual Meeting
Evaluation of 14-3-3η As a Tool for Diagnosis of Early RA in a European Cohort
Monika Hansson¹, Linda Mathsson-Alm², Anthony Marotta³ and Sascha Swiniarski⁴, ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Thermo Fisher Scientific, Uppsala, Sweden, ³Augurex Life Sciences Corp., Vancouver, BC, Canada, ⁴ImmunoDiagnostics Division Thermo Fisher Scientific, Phadia GmbH, Freiburg, Germany
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) coupled with an effective treatment strategy is a key imperative in the effective management of disease. Anti-citrullinated peptide…
Abstract Number: 1667 • 2016 ACR/ARHP Annual Meeting
Diagnostic Value of Anti-CD74 Antibodies in Axial Spondyloarthritis: Results from a Population with Low HLA-B27 Prevalence Background
Nelly Ziade¹, Fouad Fayad¹, Iyad Mallak², Georges Merheb³, Torsten Witte⁴ and Xenofon Baraliakos⁵, ¹Rheumatology, Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, ²Radiology, Hotel-Dieu de France and Saint-Joseph University, Beirut, Lebanon, ³Internal Medicine, Notre Dame des Secours University Hospital, Jbeil, Lebanon, ⁴Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ⁵Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is still frequently diagnosed late and its pathogenesis is still unclear. Although a strong genetic association of axSpA with HLA-B27 is…
Abstract Number: 2421 • 2016 ACR/ARHP Annual Meeting
Cell-Bound Complement Activation Products Correlate with Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
Joyce Hui-Yuen¹, Derren Barken², John Conklin³, Tyler O'Malley⁴, Andrew Eichenfield⁵, Amy Starr⁶, Lisa F. Imundo⁷, Thierry Dervieux⁸ and Anca D. Askanase⁹, ¹North Shore-Long Island Jewish Health System, Lake Success, NY, ²Exagen Diagnostics, Inc., Vista, CA, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴Research and Development, Exagen Diagnostics, Vista, CA, ⁵Morgan Stanley Children's Hospital of NY-Presbyterian, Columbia University, New York, NY, ⁶Pediatric Rheumatology, Columbia University Medical Center, New York, NY, ⁷Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY, ⁸Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁹Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CB-CAPs) have been demonstrated to be sensitive and…
Abstract Number: 2640 • 2016 ACR/ARHP Annual Meeting
Can GP88 (Progranulin) be Used to Predict the Efficacy of Infliximab?
Masao Sato¹, Masao Takemura², Yasuko Yamamoto³ and Kuniaki Saito⁴, ¹Rheumatology, Matsunami General Hospital, Gifu, Japan, ²Advanced Diagnostic System Research Laboratory, Fujita Health University, Toyoake, Japan, ³Disease Control and Prevention, Fujita Health University, Toyoake, Japan, ⁴Disease Control and Prevention, Fjita Health University, Aichi, Japan
Background/Purpose: GP88 (progranulin; PGRN) is a glycoprotein with a molecular weight of approximately 88,000 Da and is thought to play an important role in…
Abstract Number: 3180 • 2016 ACR/ARHP Annual Meeting
Utility of Measurements of Urinary Soluble CD163 & MCP-1 in the Identification of Subtle Renal Flares in ANCA-Associated Vasculitis
Sarah M Moran¹, Michelle Ryan¹, Paul A. Monach², David Cuthbertson³, Simon Carette⁴, Jean Dunne⁵, Gary S. Hoffman⁶, Nader A. Khalidi⁷, Curry L. Koening⁸, Carol A. Langford⁹, Carol A. McAlear¹⁰, Larry W. Moreland¹¹, Christian Pagnoux⁴, Philip Seo¹², Ulrich Specks¹³, Antoine G. Sreih¹⁴, Steven R. Ytterberg¹⁵, Lina Zgaga¹⁶, Peter A. Merkel¹⁷, Mark A. Little¹⁸ and the Vasculitis Clinical Research Consortium, ¹Clinical Medicine, Trinity Health Kidney Centre, Dublin, Ireland, ²Rheumatology, Boston University School of Medicine, Boston, MA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Immunology Department, St James's Hospital, Dublin, Ireland, ⁶Rheumatology, Cleveland Clinic, Cleveland, OH, ⁷McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁸Rheumatology, University of Utah, Salt Lake City, UT, ⁹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹²Medicine, Johns Hopkins University, Baltimore, MD, ¹³Mayo Clinic, Rochester, MN, ¹⁴Rheumatology, The University of Pennsylvania, Philadelphia, PA, ¹⁵Rheumatology, Mayo Clinic, Rochester, MN, ¹⁶Public Health and Primary Care, Trinity College Dublin, Dublin, Ireland, ¹⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁸Clinical Medicine, Trinity College Dublin, Dublin, Ireland
Background/Purpose: Prior work has shown that urinary soluble CD163 (usCD163) displays excellent biomarker characteristics for detection of active renal vasculitis using samples from patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].